EGFR Y764_V765insHH

CI-VAR-00004844Explore in graph →CIViC 1665

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
EGFR Y764_V765insHH	Erlotinib	Predictive	D	Supports Resistance	—	accepted	EID4800 In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
EGFR Y764_V765insHH	Gefitinib	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID5937 A 66 year old male with 10 pack year smoking history and lung adenocarcinoma with EGFR Y764_V765insHH mutation was given gefitinib as first line treatment, and had stable disease as best response with… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.